DCGI Serum Institute initiates phase 2, 3 clinical study on 1,600 volunteers for potential COVID-19 vaccine Newsroom Staff August 19, 2020
DCGI Biocon drug Itolizumab receives DCGI nod for use in moderate to severe COVID-19 patients Newsroom Staff August 19, 2020
